ArticleOphthalmology and therapy2026
Clinical Outcomes of Individualized Office-Based Vision Therapy for Intermittent Exotropia: A Retrospective Cohort Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionVision therapy (VT) has been proposed as a nonsurgical treatment option for intermittent exotropia (IXT), although evidence regarding the optimal treatment dosage remains limited. This study aims to investigate the relationships between VT dosage and baseline demographic and clinical characteristics of treatment outcomes in IXT.
methodsPatients with IXT who underwent office-based VT between July 2020 and March 2024 at Changsha Aier Eye Hospital were included. Treatment outcome was classified as functional recovery (yes/no), defined by prespecified thresholds for fusion on the Worth Dot test (33 cm, 1 m, and 3 m), stereoacuity (distance and near), and convergence amplitudes. Binary logistic regression was used to evaluate associations between baseline characteristics and VT dosage on treatment outcomes. The Benjamini-Hochberg procedure was used to adjust P values and maintain the false discovery rate at 5%.
resultsAmong 636 patients, 296 (46.5%) achieved functional recovery (38.5% in the ten-session group, 46.5% in the 20-session group, and 52.9% in the ≥ 30-session group). After adjustment for baseline fusion status, stereoacuity, and convergence amplitudes, each additional ten VT sessions was associated with a 5% increase in the odds of functional recovery (odds ratio, OR = 1.05, 95% CI 1.02-1.07; P = 0.003). Patients with better baseline Worth Dot fusion at 3 m were more likely to meet recovery criteria (OR = 1.28 per 1-point increase, 95% CI 1.12-1.48; P < 0.001). Moreover, worse baseline stereoacuity at near (OR = 0.43 per 1-log10 arcsec increase, 95% CI 0.30-0.62; P < 0.001) and far (OR = 0.12 per 1-log10 arcsec increase, 95% CI 0.06-0.23; P < 0.001) were associated with a reduced likelihood of functional recovery. Age, gender, treatment frequency, baseline Worth Dot at 33 cm or 1 m, and baseline convergence amplitudes were not associated with outcomes. Significant improvements were observed for nearly all measured clinical parameters.
conclusionsOffice-based VT was associated with functional recovery in patients with IXT, with greater gains in those who received more therapy sessions and had better baseline binocular function. Prospective, randomized trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.